{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:28:07Z","timestamp":1790375287314,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2019,6,14]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In November 2017, the Food and Drug Administration (FDA) approved a version of a second-generation antipsychotic, aripiprazole, embedded with a sensor (Abilify MyCite).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To systematically review the evidence supporting the FDA\u2019s approval of digital aripiprazole and how that evidence was disseminated in the scientific literature and news reports.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Study selection<\/jats:title>\n<jats:p>Prospective, double-blind, randomised controlled trials (RCTs), non-randomised and non-comparative studies were included if they focused on the use of digital aripiprazole. All scientific publications citing the trials were included if written in English. For the news reports, all languages were included if an English translation was available, and all records that were published after FDA approval were included.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Findings<\/jats:title>\n<jats:p>In the primary evidence search, no RCT comparing digital aripiprazole with a non-digital formulation, other active comparators or placebo was found. Only three non-comparative uncontrolled cohorts were found. No study provided data on remission, quality of life or any efficacy outcome. Fourteen scientific papers were identified that cited the trials and 70 news stories met the inclusion criteria. Almost 80% (11\/14) of the scientific papers and three-fourths (52\/70) of the news stories conveyed an unsupported impression of benefit.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Regulatory approval for this first-ever digital drug was based on weak evidence, and there was no evidence of better adherence with the digital version of aripiprazole compared with the non-digital version. The possibilities afforded by this technology make room for a new type of evergreening (ie, patenting of older drugs with a sensor as a \u2018new invention\u2019). Both the scientific literature and news reports conveyed an unsupported impression of benefit.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>CRD42018089515.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjebm-2019-111204","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T04:24:04Z","timestamp":1563510244000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media"],"prefix":"10.1136","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3101-5726","authenticated-orcid":false,"given":"Lisa","family":"Cosgrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-7076","authenticated-orcid":false,"given":"Ioana Alina","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-4620","authenticated-orcid":false,"given":"Allen F","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-3801","authenticated-orcid":false,"given":"Florian","family":"Naudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"2024101904301132000_24.6.231.1","unstructured":"IQVIA. The Global Use of Medicine in 2019 and Outlook to 2023: Forecasts and Areas to Watch. 2019. https:\/\/www.iqvia.com\/institute\/reports\/the-global-use-of-medicine-in-2019-and-outlook-to-2023 (Accessed May 2019)."},{"key":"2024101904301132000_24.6.231.2","first-page":"35","article-title":"Adherence and health care costs","volume":"7","author":"Iuga","year":"2014","journal-title":"Risk Manag Healthc Policy"},{"key":"2024101904301132000_24.6.231.3","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.23.2.207"},{"key":"2024101904301132000_24.6.231.4","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000393"},{"issue":"Suppl 2","key":"2024101904301132000_24.6.231.5","first-page":"A30","article-title":"64 Pharmacovigilance and participatory medicine through social media \u2013 we are still not there","volume":"23","author":"Quattri","year":"2018","journal-title":"BMJ Evidence-Based Medicine"},{"key":"2024101904301132000_24.6.231.6","unstructured":"Belluck P . First digital pill approved to worries about biomedical \u2018big brother\u2019: New York Times, 2017."},{"key":"2024101904301132000_24.6.231.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2002173"},{"key":"2024101904301132000_24.6.231.8","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2016-110570"},{"key":"2024101904301132000_24.6.231.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2018-110963"},{"key":"2024101904301132000_24.6.231.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050095"},{"key":"2024101904301132000_24.6.231.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7015"},{"key":"2024101904301132000_24.6.231.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d8164"},{"key":"2024101904301132000_24.6.231.13","first-page":"185","article-title":"Sensationalism in the media: when scientists and journalists may be complicit collaborators","volume":"4","author":"Ransohoff","year":"2001","journal-title":"Eff Clin Pract"},{"key":"2024101904301132000_24.6.231.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6106"},{"key":"2024101904301132000_24.6.231.15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1211\/ijpp.16.4.0004","article-title":"A content analysis of prescription drug information in the UK print news media","volume":"16","author":"Prosser","year":"2008","journal-title":"Int J Pharm Pract"},{"key":"2024101904301132000_24.6.231.16","unstructured":"Brown T . 100 most prescribed, best selling branded drugs through September: Medscape Medical News, 2014."},{"key":"2024101904301132000_24.6.231.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000434"},{"key":"2024101904301132000_24.6.231.18","unstructured":"Collaboration C. Cochrane handbook for systematic reviews of interventions: Cochrane Collaboration, 2008."},{"key":"2024101904301132000_24.6.231.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2024101904301132000_24.6.231.20","unstructured":"Joanna Briggs Institute. The Joanna Briggs Institute system for the unified management, assessment and review of information. User Guide Version, 4, 2007."},{"key":"2024101904301132000_24.6.231.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001308"},{"key":"2024101904301132000_24.6.231.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.020"},{"key":"2024101904301132000_24.6.231.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140889","article-title":"Interpretation of results of studies evaluating an intervention highlighted in google health news: a cross-sectional study of news","volume":"10","author":"Haneef","year":"2015","journal-title":"PLoS One"},{"key":"2024101904301132000_24.6.231.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017425","article-title":"Interpretation of health news items reported with or without spin: protocol for a prospective meta-analysis of 16 randomised controlled trials","volume":"7","author":"Haneef","year":"2017","journal-title":"BMJ Open"},{"key":"2024101904301132000_24.6.231.25","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S116029"},{"key":"2024101904301132000_24.6.231.26","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S143091"},{"key":"2024101904301132000_24.6.231.27","unstructured":"Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness: guidance for industry 2016, 2016."},{"key":"2024101904301132000_24.6.231.28","unstructured":"Food and Drug Administration. Clinical Review: aripiprazole + MIND1 system (Abilify Mycite). Center for Drug Evaluation and Research Clinical Review(s), 2017."},{"key":"2024101904301132000_24.6.231.29","doi-asserted-by":"crossref","unstructured":"Khanna P , Suo T , Komossa K , et al . Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014;18.doi:10.1002\/14651858.CD006569.pub5","DOI":"10.1002\/14651858.CD006569.pub4"},{"key":"2024101904301132000_24.6.231.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7202"},{"key":"2024101904301132000_24.6.231.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1716206"},{"key":"2024101904301132000_24.6.231.32","unstructured":"statista. Worldwide revenue of Abilify from 2011 to 2016, by region (in million U.S. dollars): The Statistics Portal. 2017. https:\/\/www.statista.com\/statistics\/312355\/abilify-worldwide-revenues-by-region\/ (Accessed Apr 2019)."},{"key":"2024101904301132000_24.6.231.33","doi-asserted-by":"crossref","unstructured":"Feldman R . May Your Drug Price Be Ever Green (October 29, 2017) UC Hastings Research Paper No 256, 2017.","DOI":"10.2139\/ssrn.3061567"},{"key":"2024101904301132000_24.6.231.34","unstructured":"Sagonowsky E . Pharma\u2019s pervasive \u2019evergreening\" is driving prices up, study says. 2017. www.fiercepharma.com\/pharma\/pharma-s-pervasive-evergreening-driving-prices-up-study-says (Accessed May 2019)."},{"key":"2024101904301132000_24.6.231.35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001460."},{"key":"2024101904301132000_24.6.231.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148939","article-title":"Is patent \"evergreening\" restricting access to medicine\/device combination products?","volume":"11","author":"Beall","year":"2016","journal-title":"PLoS One"},{"key":"2024101904301132000_24.6.231.37","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.109-4466"},{"key":"2024101904301132000_24.6.231.38","unstructured":"Correa CM . Guidelines for pharmaceutical patent examination: examining pharmaceutical patents from a public health perspective. New York City (NY): United Nations Development Programme, 2016."},{"key":"2024101904301132000_24.6.231.39","unstructured":"goodrx.com. Abilify Mycite: Prices for 1 kit (30 tablets and 7 patches) of Abilify Mycite 10mg 2019. https:\/\/www.goodrx.com\/abilify-mycite (Accessed May 2019)."},{"key":"2024101904301132000_24.6.231.40","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2016.303269"},{"key":"2024101904301132000_24.6.231.41","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2017-110845"},{"key":"2024101904301132000_24.6.231.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422206"},{"key":"2024101904301132000_24.6.231.43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a930"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2019-111204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:32:16Z","timestamp":1729582336000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2019-111204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,11,21]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjebm-2019-111204"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2019-111204","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]}}}